Solid tumour vaccine - Northwest Biotherapeutics
Alternative Names: DCVax®-Direct; DCVax®-Direct adjuvant cancer therapy; DCVax®-Head & Neck; DCVax®-Liver; DCVax®-Lung; DCVax®-PancreasLatest Information Update: 17 Oct 2023
At a glance
- Originator Northwest Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 13 Oct 2023 Northwest Biotherapeutics plans a phase-II trials for Solid tumours
- 11 Mar 2023 Northwest Biotherapeutics plans a phase II trial in Solid tumours (Inoperable/Unresectable)
- 20 Aug 2018 Northwest Biotherapeutics and Mayo Clinic plans a phase Ib trial for Brain metastases from non-small cell lung cancer or breast cancer (Inoperable/Unresectable) in USA (Intratumoural) (NCT03638765)